PDS Biotech Reports P-II Clinical Trial Results of Triple Combination Therapy for Human Papillomavirus-Positive Cancers
Shots:
- The interim results from the P-II trial evaluating the triple combination of PDS0101 + M9241 (tumor-targeting IL-12 fusion protein) & bintrafusp alfa (bifunctional fusion protein targeting PD-L1 & TGF-β) in 40 CPI-naïve & CPI-refractory patients with advanced HPV+ anal, cervical, head & neck, vaginal, and vulvar cancers
- The results showed m-OS (21mos.) in 29 CPI refractory patients with ORR (63%) who received the optimal dose of the triple combination. In CPI naïve, 75% were alive at a median follow-up of 27mos., m-OS not reached, ORR (88%), historically m-OS was 3-4mos & 7-11mos. in CPI refractory & naïve disease
- Grade 3 TRAEs (48%) and grade 4 AEs (4%) over 70% received the combination of CPIs and CT reporting grade ≥3 TRAEs
Ref: Globe Newswire | Image: PDS
Related News:- PDS Biotech Provides Updates of PDS0101 + Keytruda (pembrolizumab) in P-II (VERSATILE-002) Trial for Advanced Head and Neck Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
